Neurocrine Bio. (NBIX) PT Raised to $145 at RBC Capital Following 'Surprising Commercial Momentum'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Neurocrine Bio. (NASDAQ: NBIX) to $145.00 (from $137.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
